While our study was not powered sufficiently to detect a statistically significant molecular signature unique to either HiDAC/MITO responsive or non-responsive patients, we did find that the non-responding patient subset was enriched for TP53 mutations which is in line with previous publications corroborating the detrimental impact of TP53 in AML patients [47]. Here, TP53 is linked to acute myeloid leukemia.